

Serbian Biochemical Society

President: Marija Gavrović-Jankulović

Vice-president: Suzana Jovanović-Šanta

General Secretary: Isidora Protić-Rosić

Treasurer: Milica Popović

Scientific Board

Marija Gavrović-
Jankulović

Mihajlo B. Spasić

Vesna Niketić

Ivanka Karadžić

Svetlana Dinić

Nevena Đukić

Jelena Bašić

Ivan Spasojević

Ivana Beara

Mojca Stojiljković

Andjelka Celić

Željko Popović

Žanka Bojić

Trbojević

Milan Nikolić

Ana Ninić

Adela Pitea

Zupkó István

Vlatka Zoldos

Aleksandra Inić-

Kanada

Tomasz Jurkowski

Yaraslau Dzichenka

Brankica Janković

Sanja Krstić

Organization Committee

Suzana Jovanović-
Šanta

Jelena Purać

Milica Popović

Emilija Svirčev

Miloš Opačić

Milena Dimitrijević

Tatjana Majkić

Sofija Bekić

Diandra Pintać

Isidora Protić-Rosić

Marina Crnković

Maja Marinović

Iva Uzelac

Jovana Drljača

Miloš Avramov

Srdana Đorđievski

Milana Bosanac

Vanja Tatić

Proceedings

Editor: Ivan Spasojević

Technical support: Jelena Korać Jačić

Cover design: Zoran Beloševac

Publisher: Faculty of Chemistry, Serbian Biochemical Society

Printed by: Colorgrafx, Belgrade

Serbian Biochemical Society

Eleventh Conference

Scientific meeting of an international character

September 22nd and 23rd, 2022, Novi Sad, Serbia

“Amazing Biochemistry”

Cisplatin-ibuprofen conjugate free and immobilised in mesoporous silica nanoparticle SBA-15 indicate high antiproliferative potential on mouse cancer cell lines

Teodora Komazec^{1*}, Dijana Drača¹, Sanja Mijatović¹, Ivana Predarska^{2,3}, Goran N. Kaluderović², Evamarie Hey-Hawkins³, Danijela Maksimović-Ivanić¹

¹*Department of Immunology, Institute for Biological Research “Siniša Stanković”, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia*

²*Department of Engineering and Natural Sciences, University of Applied Sciences Merseburg, Merseburg, Germany*

³*Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Leipzig, Germany*

**e-mail: teodora.komazec@ibiss.bg.ac.rs*

From its discovery, cisplatin therapy has widely been associated with toxicity and severe side effects. Platinum(IV) complexes, as well as immobilising them in nanomaterials could help to overcome these problems. Cyclooxygenase-2 (COX-2) is involved in cancer progression,¹ which encourages the development of inhibitors of COX enzymes in antitumour therapy. To determine the potential cytotoxic effect, a cisplatin-ibuprofen conjugate in free form, as well as loaded into SBA-15 nanomaterial, was tested on 4T1, CT26, B16 and MC38 cell lines. The results of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and crystal violet viability assays showed that both agents dose-dependently decreased the number of viable cells of all tested cell lines. Flow cytometric analysis revealed significant decrease in the division potential of B16-treated cells. In further investigations, activation of caspases proved by ApoStat assay was noticed; however, apoptosis was not identified by flow cytometry in culture of treated B16 cells. Finally, light microscopy evaluation revealed the presence of enlarged cells with prominent heterochromatin foci in nuclei upon the treatment indicating that cells entered senescent state. High antitumour potential defined at the nanomolar concentration on mouse melanoma cells make cisplatin-ibuprofen a suitable candidate for further research.

Acknowledgements

This study was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, grant number 451-03-68/2022-14/200007

References

1. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. *Nat Rev Canc* 2006;6:130-40.